Transforming Psychedelics into Approved Medicines
K. Liszewski
Genetic Engineering & Biotechnology News October 1, 2022 DOI: 10.1089/gen.42.10.13 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Interventions | Synthetic psilocybin (COMP360) psychological support |
| Key points | Reports that Compass Pathways is developing a psilocybin therapy model combining synthetic psilocybin with psychological support, and has announced a Phase II trial of its synthetic psilocybin (COMP360) in patients with anorexia nervosa. No results or efficacy data are presented. |
Abstract
A new model of psilocybin therapy is being developed by Compass Pathways, a mental health company. This model involves the administration of a synthetic psilocybin in conjunction with psychological support in order to treat conditions such as treatment-resistant depression. Most recently, Compass announced the launch of a Phase II trial to investigate the efficacy of its synthetic psilocybin (COMP360) in patients with anorexia nervosa.